SubsidieMeestersNEXT GENERATION IMAGING FOR REAL-TIME DOSE VERIFICATION ENABLING ADAPTIVE PROTON THERAPY
The NOVO project aims to develop a groundbreaking real-time dose verification technology for proton radiotherapy, enhancing personalized cancer treatment and improving patient outcomes.
Projectdetails
Introduction
The NOVO project will address a fundamental issue in proton radiotherapy (PT) of cancer, namely the lack of real-time dose verification (RDV) that significantly limits the potential of PT due to uncertainties in the precise delivery of the prescribed dose.
Project Goals
In the NOVO project, we will develop the first proof-of-concept of an RDV technology adaptable to any PT treatment and bring the concept to TRL 4 by also considering integration into the PT clinical workflow.
Importance of RDV Technology
The RDV technology will be pivotal for enabling the next generation of adaptive PT therapy, i.e., dose-guided real-time adaptive therapy. Real-time measurement of the dose to targeted and non-targeted tissues will be the key to truly empower patient-centered, personalized cancer treatment, which is important to improve curation and quality of life post-treatment.
Project Characteristics
As a high-risk/high-gain project, NOVO aims at a first-of-its-kind RDV technology through the unique synergy between:
- Cutting-edge, inexpensive organic scintillator technology that can detect secondary radiation during treatment for non-invasive measurements.
- Novel and fast image reconstruction, artificial intelligence (AI)-accelerated models, and AI-enhanced image reconstruction to allow simultaneous detection of multiple radiation species and tissue compositional analysis.
- Tumor-tracking and imaging of tissue radio-sensitivity based on oxygen levels.
- Intelligent automation of decision-making schemes for real-time dose-guided adaptive therapy.
Impact on Proton Therapy
The project will essentially open a new era in PT that enables curing more cancer patients and reducing toxicity from treatment.
Consortium and Collaboration
The NOVO consortium covers the entire value chain of RDV development (technology providers, theory and modeling, technology integration, and PT clinics) and optimally engages nuclear, medical, and high-energy physicists, chemists, mathematicians, computer scientists, oncologists, biologists, as well as European PT centers.
Financiële details & Tijdlijn
Financiële details
| Subsidiebedrag | € 3.759.489 |
| Totale projectbegroting | € 3.759.489 |
Tijdlijn
| Startdatum | 1-3-2024 |
| Einddatum | 29-2-2028 |
| Subsidiejaar | 2024 |
Partners & Locaties
Projectpartners
- HOGSKULEN PA VESTLANDETpenvoerder
- BOGAZICI UNIVERSITESI
- HELSE BERGEN HF
- HELMHOLTZ-ZENTRUM DRESDEN-ROSSENDORF EV
- TARGET SYSTEMELEKTRONIK GMBH & CO.KG
- FRAUNHOFER GESELLSCHAFT ZUR FORDERUNG DER ANGEWANDTEN FORSCHUNG EV
- UNIVERSITETET I BERGEN
- THE UNIVERSITY OF MANCHESTER
Land(en)
Vergelijkbare projecten binnen EIC Pathfinder
| Project | Regeling | Bedrag | Jaar | Actie |
|---|---|---|---|---|
Development of innovative proton and neutron therapies with high cancer specificity by 'hijacking' the intracellular chemistry of haem biosynthesis.NuCapCure aims to develop novel cancer treatments for glioblastoma by utilizing custom-made drugs through biosynthesis to enhance proton and neutron therapies for better targeting and efficacy. | EIC Pathfinder | € 5.972.875 | 2024 | Details |
2D Material-Based Multiple Oncotherapy Against Metastatic Disease Using a Radically New Computed Tomography ApproachPERSEUS aims to develop a novel nanotechnology-based cancer therapy that activates under CT imaging to treat deep-seated, drug-resistant tumors with minimal side effects. | EIC Pathfinder | € 2.740.675 | 2023 | Details |
Next generation Limited-Angle time-of-flight PET imagerThe PetVision project aims to develop a cost-effective, modular PET imaging device with enhanced sensitivity to improve cancer diagnostics accessibility across various medical settings. | EIC Pathfinder | € 3.374.041 | 2023 | Details |
Live Cell Spectroscopy Analysis for Personalised Particle Radiation Therapy of Metastatic Bone CancerBoneOscopy aims to revolutionize metastatic bone cancer treatment by enabling daily monitoring during particle radiotherapy, enhancing personalized care and treatment efficacy. | EIC Pathfinder | € 3.069.321 | 2025 | Details |
REAL TIME MOLECULAR IMAGER WITH UNSURPASSED RESOLUTIONRETIMAGER aims to revolutionize PET imaging by achieving ten-fold improvements in spatial and temporal resolution, enabling real-time, high-sensitivity imaging for personalized precision medicine. | EIC Pathfinder | € 3.126.347 | 2023 | Details |
Development of innovative proton and neutron therapies with high cancer specificity by 'hijacking' the intracellular chemistry of haem biosynthesis.
NuCapCure aims to develop novel cancer treatments for glioblastoma by utilizing custom-made drugs through biosynthesis to enhance proton and neutron therapies for better targeting and efficacy.
2D Material-Based Multiple Oncotherapy Against Metastatic Disease Using a Radically New Computed Tomography Approach
PERSEUS aims to develop a novel nanotechnology-based cancer therapy that activates under CT imaging to treat deep-seated, drug-resistant tumors with minimal side effects.
Next generation Limited-Angle time-of-flight PET imager
The PetVision project aims to develop a cost-effective, modular PET imaging device with enhanced sensitivity to improve cancer diagnostics accessibility across various medical settings.
Live Cell Spectroscopy Analysis for Personalised Particle Radiation Therapy of Metastatic Bone Cancer
BoneOscopy aims to revolutionize metastatic bone cancer treatment by enabling daily monitoring during particle radiotherapy, enhancing personalized care and treatment efficacy.
REAL TIME MOLECULAR IMAGER WITH UNSURPASSED RESOLUTION
RETIMAGER aims to revolutionize PET imaging by achieving ten-fold improvements in spatial and temporal resolution, enabling real-time, high-sensitivity imaging for personalized precision medicine.
Vergelijkbare projecten uit andere regelingen
| Project | Regeling | Bedrag | Jaar | Actie |
|---|---|---|---|---|
Gamma-Neutron Vision aimed at improved cancer treatments in Hadron TherapyThis project aims to develop a portable device for simultaneous gamma-ray and thermal neutron imaging to enhance ion-range verification and secondary neutron dose assessment in proton therapy. | ERC Proof of... | € 150.000 | 2024 | Details |
Prompt Gamma Time Imaging: a new medical-imaging modality for adaptive Particle TherapyThe project aims to enhance particle therapy efficacy and safety by developing Prompt Gamma Time Imaging for real-time monitoring of treatment, improving dose control and adaptive dosimetry. | ERC Starting... | € 1.498.969 | 2022 | Details |
Radically New Cancer Therapy Based on Advances in Nanotechnology and Photonics for Simultaneous Imaging and Treatment of Solid TumoursScanNanoTreat aims to revolutionize cancer treatment by integrating advanced imaging and therapy technologies to improve patient outcomes and reduce costs, targeting clinical trials by 2027. | EIC Transition | € 2.499.911 | 2025 | Details |
Treatment planning assessment for the Optiflux radiosurgery systemDit project ontwikkelt een innovatieve radiotherapie met sub-MeV X-stralen voor nauwkeurige tumorbehandeling en minder schade aan omliggende organen. | Mkb-innovati... | € 20.000 | 2021 | Details |
Deciphering the radiobiology of targeted radionuclide therapy: from subcellular to intra-tumoural analysesThis project aims to enhance targeted radionuclide therapies for metastatic cancer by elucidating radiobiological mechanisms and developing advanced imaging techniques to improve treatment strategies. | ERC Starting... | € 1.750.000 | 2022 | Details |
Gamma-Neutron Vision aimed at improved cancer treatments in Hadron Therapy
This project aims to develop a portable device for simultaneous gamma-ray and thermal neutron imaging to enhance ion-range verification and secondary neutron dose assessment in proton therapy.
Prompt Gamma Time Imaging: a new medical-imaging modality for adaptive Particle Therapy
The project aims to enhance particle therapy efficacy and safety by developing Prompt Gamma Time Imaging for real-time monitoring of treatment, improving dose control and adaptive dosimetry.
Radically New Cancer Therapy Based on Advances in Nanotechnology and Photonics for Simultaneous Imaging and Treatment of Solid Tumours
ScanNanoTreat aims to revolutionize cancer treatment by integrating advanced imaging and therapy technologies to improve patient outcomes and reduce costs, targeting clinical trials by 2027.
Treatment planning assessment for the Optiflux radiosurgery system
Dit project ontwikkelt een innovatieve radiotherapie met sub-MeV X-stralen voor nauwkeurige tumorbehandeling en minder schade aan omliggende organen.
Deciphering the radiobiology of targeted radionuclide therapy: from subcellular to intra-tumoural analyses
This project aims to enhance targeted radionuclide therapies for metastatic cancer by elucidating radiobiological mechanisms and developing advanced imaging techniques to improve treatment strategies.